Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20338044 | 0.95 | MAPT (0.55) | MAPTL3MBTL1GAANR2F2RAB9A | |
| SCHEMBL20338006 | 0.94 | MAPT (0.54) | MAPTL3MBTL1GAANR2F2RAB9A | |
| SCHEMBL20338068 | 0.94 | MAPT (0.54) | MAPTL3MBTL1GAANR2F2RAB9A | |
| SCHEMBL20338003 | 0.94 | MAPT (0.52) | MAPTL3MBTL1GAANR2F2RAB9A | |
| SCHEMBL20338033 | 0.89 | MAPT (0.51) | MAPTL3MBTL1GAATHRBPOLB | |
| SCHEMBL20337992 | 0.88 | MAPT (0.51) | MAPTL3MBTL1GAATHRBLMNA | |
| SCHEMBL20338614 | 0.85 | MAPT (0.53) | MAPTL3MBTL1GAATHRBPOLB | |
| SCHEMBL20346528 | 0.84 | MAPT (0.63) | MAPTL3MBTL1GAATHRBPOLB | |
| SCHEMBL20346531 | 0.84 | MAPT (0.51) | MAPTL3MBTL1GAATHRBLMNA | |
| SCHEMBL20338056 | 0.83 | MAPT (0.55) | MAPTL3MBTL1GAATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186815-A1 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CANCER | URIFER LTD. (IL) | 2018-07-05 | — | — | US | disclosed |
| US-20180186815-A1 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CANCER | URIFER LTD. (IL) | 2018-07-05 | — | — | US | disclosed |
| US-20180186815-A1 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CANCER | URIFER LTD. (IL) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186815-A1 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, TYMP | MAPT 3767/4885L3MBTL1 4861/4885GAA 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.